A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)
Lung cancer is the leading cause of cancer-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for more than 80% of all such cancers [1]. Drugs that target specific molecular abnormalities within the tumor, such as EGFR mutations, ALK rearrangements, ROS1 rearrangements, and BRAF mutations are the preferred first-line therapies for patients with adenocarcinoma [2]. Immune checkpoint inhibitors (ICIs) with or without cytotoxic chemotherapy are also effective. Pembrolizumab monotherapy; pembrolizumab and platinum-based doublet combination; and atezolizumab, bevacizumab, and platinum-based doublet combination have been shown to have superior effectiveness over their counterparts, and have therefore been approved as first-line therapies in patients with advanced NSCLC [3 –6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Hajime Asahina, Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Masao Harada, Hiroshi Yokouchi, Kenya Kanazawa, Yuka Fujita, Tetsuya Kojima, Fumiko Sugaya, Hisashi Tanaka, Ryoichi Honda, Eiki Kikuchi, Tomoo Ikari, Takahiro Ogi, Kaoruko Shimizu, Masaru Suz Source Type: research
More News: Adenocarcinoma | Avastin | Cancer | Cancer & Oncology | Chemotherapy | Interstitial Lung Disease | Kenya Health | Lung Cancer | Non-Small Cell Lung Cancer | Study